Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Venetoclax + Azacitidine in AML-M5
NCT05566054Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tucidinostat in acute monocytic leukemia (AML-M5) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Composite Complete Remission Rate at 8 weeks and Overall Response Rate at 8 weeks. Started Mar 2022; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
acute monocytic leukemia (AML-M5)
Beyond the preview
Go deeper on NCT05566054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566054.